Appeals court ruling upholds Lilly’s Evista patents
Eli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic version of the Evista osteoporosis treatment before March 2014.
Bloomberg News
Articles
Lilly wins ban of generic Strattera pending appeal
The U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly’s request to prevent sales until the court rules on a judge’s decision invalidating a patent on the medicine.
Centaur wins approval to sell Colorado casino
Luna Gaming Central City LLC is paying $7.5 million in cash plus a $2.5 million note, less adjustments. There were no competing
bids.
Health insurer cash shifts to favor Republicans before election
Health insurers led by WellPoint Inc. are backing Republicans with campaign donations by an 8-to-1 margin, favoring the party
that’s promised to repeal President Barack Obama’s health-care overhaul if it wins back Congress.
Lilly wins further delay in sales of Strattera copies
Strattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
Lilly gains panel’s backing to expand Cymbalta use
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
Lilly wins temporary ban on sales of Strattera copies
The invalidation of Lilly’s Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
Lilly Alzheimer’s drug prospect only the latest to fail
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Visteon ordered to reinstate health care to retirees
The mandate from a U.S. bankruptcy judge will supply retroactive benefits to more than 6,000 Visteon Corp. retirees who lost
insurance coverage after
the
Michigan-based auto-parts maker filed for bankruptcy in 2009, including 2,100 workers in Indiana.
Lilly’s Cymbalta helps chronic pain in U.S. review
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
ITT, other for-profit education firms face more oversight
Shares in ITT Educational Services Inc., based in Carmel, declined 13 percent Monday morning, to $56.02 each, after being downgraded
AIG sells American General unit to Fortress at loss
American International Group Inc. has agreed to sell a majority stake in its Evansville-based consumer lending unit, getting
rid of an operation that posted about $1.7 billion in operating losses since 2008 and accumulated more than $17 billion in
debt.
WellPoint boosts debt offering to $1 billion
Proceeds from the sale will be used for working capital and general corporate purposes, including debt repayment, the company
said in a prospectus.
Simon Property plans debt sale to fund tender offer
Simon Property Group Inc., the largest U.S. shopping-mall owner, plans to sell $750 million of notes to fund a tender offer
for outstanding debt for the second time this year.
Daniels: Stimulus should focus on companies, not states
Indiana Gov. Mitch Daniels said he opposes more stimulus such as aid to states to keep teachers hired and to expand credit
to small business, while favoring incentives to revive private hiring and investment.
Consumers facing record prices for bacon
The U.S. hog-breeding herd is near the smallest on record, and wholesale pork-belly prices are up 72 percent in the past year,
to the highest price since at least 1998.
WellPoint, peers focus on health reform rules, campaign
WellPoint Inc., UnitedHealth Group Inc. and three other health insurers, criticized by Democrats during the health care reform
debate, are seeking to influence how the new law will be implemented, and possibly change it, by campaigning for supportive
congressional candidates.
Senator asks Zimmer for info about product complaints
Inquiry stemmed from an article in the New York Times about a dispute between the Warsaw-based maker of artificial hip and knee joints and two of its consultants.
Lilly among bidders for Denmark company, source says
Copenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
Investors fear insurers’ rosy outlook will boost regulators’ scrutiny
Indianapolis-based WellPoint Inc. became the third U.S. health insurer this month to increase its 2010 profit forecast, stirring
investor concern that state and federal regulators may increase scrutiny of industry pricing.